![FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC Pooled analysis finds correlations between early endpoints and OS in ICI trials](https://cdn.cancerletter.com/media/2024/03/15162217/50-11-4x3-1.jpg)
![FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC Pooled analysis finds correlations between early endpoints and OS in ICI trials](https://cdn.cancerletter.com/media/2024/03/15162217/50-11-4x3-1.jpg)
Cover Story
Conversation with The Cancer LetterRegulatory News
By Matthew Bin Han Ong and Paul Goldberg
When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- House GOP leaders propose “streamlining” NIH into 15 institutes and centers
Plan calls for slashing ARPA-H, adding oversight to infectious disease research - Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Nathan Berger, founding director of Case Comprehensive Cancer Center, dies at 83
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch